Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Capricor Therapeutics (CAPR) Interest & Investment Income (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Interest & Investment Income data on record, last reported at $1.7 million in Q3 2025.

  • For Q3 2025, Interest & Investment Income rose 278.13% year-over-year to $1.7 million; the TTM value through Sep 2025 reached $4.9 million, up 150.07%, while the annual FY2024 figure was $2.2 million, 27.44% up from the prior year.
  • Interest & Investment Income reached $1.7 million in Q3 2025 per CAPR's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.8 million in Q2 2025 and bottomed at $9165.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $460372.6, with a median of $416442.0 recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: tumbled 59.61% in 2021, then surged 2998.53% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $15984.0 in 2021, then skyrocketed by 2275.49% to $379699.0 in 2022, then grew by 19.09% to $452199.0 in 2023, then soared by 51.83% to $686572.0 in 2024, then skyrocketed by 149.57% to $1.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest & Investment Income were $1.7 million in Q3 2025, $1.8 million in Q2 2025, and $729542.0 in Q1 2025.